{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002024","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.039290+00:00","generated_at":"2026-06-20T17:40:45.904697+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ironwood cuts FY2022 revenue guidance to ~$411M; issues FY2023 outlook and files sNDA for pediatric LINZESS","bullets":["Updated FY2022: total revenue ~$411M (prev. $420-430M), LINZESS net sales ~0% growth, adj. EBITDA ~$250M.","FY2023 guidance: revenue $420-435M, LINZESS net sales growth 3-5%, adj. EBITDA >$250M.","sNDA submitted to FDA for LINZESS in functional constipation in children 6-17; if approved, first FDA therapy for this population.","Expects ~$650M cash at YE2022; high single-digit LINZESS prescription demand growth in 2023.","Clinical milestone: CNP-104 data expected in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002024","json":"https://secwatch.observer/filing/0001104659-23-002024.json","markdown":"https://secwatch.observer/filing/0001104659-23-002024.md","text":"https://secwatch.observer/filing/0001104659-23-002024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923002024/0001104659-23-002024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923002024/tm232274d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:40:45.904697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9a6b776b28c050a5ad6310649a39527c839c891","claim":"IRONWOOD PHARMACEUTICALS INC reported full year 2022 results: revenue ~$411 million. Guidance reaffirmed.","evidence_excerpt":"expects: Previous 2022 Guidance (November 2022) Updated 2022 Guidance 1 LINZESS U.S. net sales growth 2 Low single digits % ~0% Total revenue $420 - $430 million ~$411 million Adjusted EBITDA 3 >$250 million ~$250 million Full Year 2023 Financial Guidance The table below summarizes Ironwood’s full year 2023 guidance. Ironwood expects: 2023 Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923002024/0001104659-23-002024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"~$411 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}